- Report
- January 2022
- 60 Pages
Global
From €3797EUR$3,950USD£3,256GBP
- Report
- March 2021
- 75 Pages
Global
€21145EUR$22,000USD£18,133GBP
- Report
- August 2022
Global
From €759EUR$790USD£651GBP
- Report
- August 2022
Global
From €759EUR$790USD£651GBP
- Report
- August 2022
Global
From €759EUR$790USD£651GBP
- Report
- August 2022
Global
From €759EUR$790USD£651GBP
- Report
- August 2022
United States
From €1865EUR$1,940USD£1,599GBP
- Report
- February 2021
Global
From €2845EUR$2,960USD£2,440GBP
- Report
- February 2021
Global
From €2845EUR$2,960USD£2,440GBP
- Clinical Trials
- November 2021
- 724 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Drug Pipelines
- August 2020
- 537 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- October 2023
- 105 Pages
Global
From €3500EUR$3,901USD£3,106GBP
- Drug Pipelines
- June 2021
- 682 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- May 2022
- 68 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- October 2022
- 265 Pages
Global
From €5507EUR$5,730USD£4,723GBP
The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators.
Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more
